Genelux (GNLX) Revenue & Revenue Breakdown
Genelux Revenue Highlights
Latest Revenue (Y)
$170.00K
Latest Revenue (Q)
$8.00K
Genelux Revenue by Period
Genelux Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $170.00K | -98.46% |
| 2022-12-31 | $11.07M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Genelux generated $170.00K in revenue during NA 2023, up -98.46% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Genelux Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $8.00K | -99.45% |
| 2023-12-31 | $1.46M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $170.00K | 150.00% |
| 2022-12-31 | $68.00K | -99.38% |
| 2022-09-30 | $11.00M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Genelux generated $8.00K in revenue during Q1 2024, up -99.45% compared to the previous quarter, and up 11.76% compared to the same period a year ago.
Genelux Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| IVA | Inventiva | $17.50M | $15.58M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| IKNA | Ikena Oncology | $9.16M | - |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| DYAI | Dyadic | $2.90M | $334.62K |
| GNLX | Genelux | $170.00K | $8.00K |
| CGEM | Cullinan Oncology | - | - |
| IMRX | Immuneering | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| CING | Cingulate | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| CELC | Celcuity | - | - |
| LRMR | Larimar Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| CMPX | Compass Therapeutics | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
GNLX Revenue FAQ
What is Genelux’s yearly revenue?
Genelux's yearly revenue for 2023 was $170K, representing a decrease of -98.46% compared to 2022. The company's yearly revenue for 2022 was $11.07M, representing an increase of 100.00% compared to 2021. GNLX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Genelux’s quarterly revenue?
Genelux's quarterly revenue for Q1 2024 was $8K, a -99.45% decrease from the previous quarter (Q4 2023), and a -95.29% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.46M, a 100.00% increase from the previous quarter (Q3 2023), and a 2052.94% increase year-over-year (Q4 2022). GNLX's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a -100.00% decrease year-over-year (Q3 2022).
What is Genelux’s revenue growth rate?
Genelux's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.